PEGylated Proteins Industry Forecast 2025-2034: Market Expansion, Trends, and Competitive Landscape
The pegylated proteins market size has grown rapidly in recent years. It will grow from $1.47 billion in 2024 to $1.68 billion in 2025 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to improved therapeutic efficacy, a growing aging population, demand for long-acting formulations, enhanced drug safety profiles, and expanding applications including targeted drug delivery systems.
The pegylated proteins market size is expected to see rapid growth in the next few years. It will grow to $2.8 billion in 2029 at a compound annual growth rate (CAGR) of 13.7%. The growth in the forecast period can be attributed to increasing investment in rare diseases, rapid growth of the biopharmaceutical industry, precision medicine tailoring, increasing competition from biosimilar versions of biologic drugs, and adoption of innovative market access strategies. Major trends in the forecast period include the integration of digital health technologies, next-generation pegylation technologies, customized formulations for precision medicine, a focus on combination therapies, and a shift towards patient-centric healthcare models.
Get Your Free Sample of The Global PEGylated Proteins Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16145&type=smp
What have been the primary factors driving the pegylated proteins market’s growth?
The increasing prevalence rate of lifestyle diseases is expected to propel the growth of the PEGylated proteins market going forward. Lifestyle diseases refer to health conditions primarily caused by unhealthy habits and lifestyle choices such as poor diet, lack of physical activity, and smoking. Lifestyle diseases are on the rise due to a combination of factors such as less physical activity, unhealthier diets high in processed foods, and increased stress. PEGylated proteins are utilized in treating lifestyle diseases by enhancing the efficacy, duration, and targeted delivery of therapeutic agents for conditions including cardiovascular diseases, diabetes, and certain cancers. For instance, in May 2024, according to the Office for Health Improvement and Disparities, a UK-based government agency, in 2022 to 2023, an estimated 64.0% of adults aged 18 and over in England were classified as overweight or living with obesity, showing a slight increase from 63.8% in 2021 to 2022. Therefore, the increasing prevalence rate of lifestyle diseases is driving the growth of the PEGylated proteins market.
What are the key segments within the pegylated proteins market?
The pegylated proteins market covered in this report is segmented –
1) By Product: Consumable And Services, PEGylation Kits And Reagents, Monofunctional Linear PEGs, Bifunctional PEGs, Services, Other Products
2) By Protein Type: Colony Stimulating Factors, Interferons, Erythropoietin, Recombinant Factor VII, Other Protein Types
3) By Application: Cancer Treatment, Hepatitis, Chronic Kidney Diseases, Hemophilia, Multiple Sclerosis, Gastrointestinal Disorders, Other Applications
4) By End User: Pharmaceuticals, Biotechnology Companies, Contract Research Organizations, Academic Research Institutes
Subsegments:
1) By Consumable And Services: Consumables, Services (Contract Services, PEGylation Services)
2) By PEGylation Kits And Reagents: PEGylation Kits, Reagents
3) By Monofunctional Linear PEGs: Monofunctional PEGs For Protein Modification
4) By Bifunctional PEGs: Bifunctional PEGs For Protein Modification
5) By Other Products: Conjugates, PEGylated Drugs And Therapeutics
Order your report now for swift delivery
https://www.thebusinessresearchcompany.com/report/pegylated-proteins-global-market-report
Which key players are shaping the pegylated proteins market?
Major companies operating in the PEGylated proteins market are Merck & Co. Inc., Bayer AG, Bristol Myers Squibb Company, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc., Novo Nordisk A/S, Evonik Industries AG, Viatris Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Lonza Group Ltd., Jazz Pharmaceuticals plc, Ipsen Pharma, Kyowa Kirin Co. Ltd., WuXi Biologics, BioMarin Pharmaceutical Inc., Ligand Pharmaceuticals Incorporated, Zydus Cadila, Enzon Pharmaceuticals Inc.
How will emerging trends drive the pegylated proteins market throughout the forecast period?
Major companies operating in the PEGylated protein market are developing innovative products, such as PEGylation reagents, to gain a competitive edge in the market. PEGylation reagents refer to chemical compounds that attach polyethylene glycol (PEG) chains to biomolecules, altering their properties for various biomedical applications. For instance, in May 2023, Creative Enzymes, a US-based supplier of food additives and enzymes, launched DSPE-PEG-Maleimide for targeted drug delivery. DSPE-PEG-Maleimide (DSPE-PEG-MAL) is a linear heterobifunctional PEGylation reagent containing DSPE phospholipids and maleimide. It is a useful self-assembly reagent that can be used to prepare PEGylated liposomes or micelles, and it also provides thiol or cysteine reactive maleimide groups. It is often used in targeted drug delivery.
How do regional factors impact the pegylated proteins market, and which region is the largest contributor?
North America was the largest region in the PEGylated Proteins market in 2024. The regions covered in the PEGylated proteins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The PEGylated Proteins Market Report 2025 Offer?
The pegylated proteins market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
PEGylated proteins are therapeutic proteins covalently attached to polyethylene glycol (PEG) to enhance their pharmacokinetic properties and reduce immunogenicity, thus improving therapeutic efficacy. They are utilized in various medical applications, including drug delivery, diagnostics, and targeted therapy, offering prolonged action and improved patient outcomes.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=16145
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Comments
Post a Comment